Literature DB >> 17058078

Target volume definition for 18F-FDG PET-positive lymph nodes in radiotherapy of patients with non-small cell lung cancer.

Ursula Nestle1, Andrea Schaefer-Schuler, Stephanie Kremp, Andreas Groeschel, Dirk Hellwig, Christian Rübe, Carl-Martin Kirsch.   

Abstract

PURPOSE: FDG PET is increasingly used in radiotherapy planning. Recently, we demonstrated substantial differences in target volumes when applying different methods of FDG-based contouring in primary lung tumours (Nestle et al., J Nucl Med 2005;46:1342-8). This paper focusses on FDG-positive mediastinal lymph nodes (LN(PET)).
METHODS: In our institution, 51 NSCLC patients who were candidates for radiotherapy prospectively underwent staging FDG PET followed by a thoracic PET scan in the treatment position and a planning CT. Eleven of them had 32 distinguishable non-confluent mediastinal or hilar nodal FDG accumulations (LN(PET)). For these, sets of gross tumour volumes (GTVs) were generated at both acquisition times by four different PET-based contouring methods (visual: GTV(vis); 40% SUVmax: GTV40; SUV=2.5: GTV2.5; target/background (T/B) algorithm: GTV(bg)).
RESULTS: All differences concerning GTV sizes were within the range of the resolution of the PET system. The detectability and technical delineability of the GTVs were significantly better in the late scans (e.g. p = 0.02 for diagnostic application of SUVmax = 2.5; p = 0.0001 for technical delineability by GTV2.5; p = 0.003 by GTV40), favouring the GTV(bg) method owing to satisfactory overall applicability and independence of GTVs from acquisition time. Compared with CT, the majority of PET-based GTVs were larger, probably owing to resolution effects, with a possible influence of lesion movements.
CONCLUSION: For nodal GTVs, different methods of contouring did not lead to clinically relevant differences in volumes. However, there were significant differences in technical delineability, especially after early acquisition. Overall, our data favour a late acquisition of FDG PET scans for radiotherapy planning, and the use of a T/B algorithm for GTV contouring.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17058078     DOI: 10.1007/s00259-006-0252-x

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  29 in total

1.  18F-deoxyglucose positron emission tomography (FDG-PET) for the planning of radiotherapy in lung cancer: high impact in patients with atelectasis.

Authors:  U Nestle; K Walter; S Schmidt; N Licht; C Nieder; B Motaref; D Hellwig; M Niewald; D Ukena; C M Kirsch; G W Sybrecht; K Schnabel
Journal:  Int J Radiat Oncol Biol Phys       Date:  1999-06-01       Impact factor: 7.038

2.  FDG-PET in radiotherapy treatment planning: Pandora's box?

Authors:  Arnold C Paulino; Peter A S Johnstone
Journal:  Int J Radiat Oncol Biol Phys       Date:  2004-05-01       Impact factor: 7.038

3.  Comparison of different methods for delineation of 18F-FDG PET-positive tissue for target volume definition in radiotherapy of patients with non-Small cell lung cancer.

Authors:  Ursula Nestle; Stephanie Kremp; Andrea Schaefer-Schuler; Christiane Sebastian-Welsch; Dirk Hellwig; Christian Rübe; Carl-Martin Kirsch
Journal:  J Nucl Med       Date:  2005-08       Impact factor: 10.057

4.  Positron emission tomography in the pretreatment evaluation and follow-up of non-small cell lung cancer patients treated with radiotherapy: preliminary findings.

Authors:  M E Hebert; V J Lowe; J M Hoffman; E F Patz; M S Anscher
Journal:  Am J Clin Oncol       Date:  1996-08       Impact factor: 2.339

5.  The contribution of integrated PET/CT to the evolving definition of treatment volumes in radiation treatment planning in lung cancer.

Authors:  Hani Ashamalla; Sameer Rafla; Kapila Parikh; Bahaa Mokhtar; Ganesh Goswami; Shravan Kambam; Hussain Abdel-Dayem; Adel Guirguis; Pamela Ross; Alex Evola
Journal:  Int J Radiat Oncol Biol Phys       Date:  2005-06-24       Impact factor: 7.038

6.  Defining a radiotherapy target with positron emission tomography.

Authors:  Quinten C Black; Inga S Grills; Larry L Kestin; Ching-Yee O Wong; John W Wong; Alvaro A Martinez; Di Yan
Journal:  Int J Radiat Oncol Biol Phys       Date:  2004-11-15       Impact factor: 7.038

7.  CT and (18)F-deoxyglucose (FDG) image fusion for optimization of conformal radiotherapy of lung cancers.

Authors:  P Giraud; D Grahek; F Montravers; M F Carette; E Deniaud-Alexandre; F Julia; J C Rosenwald; J M Cosset; J N Talbot; M Housset; E Touboul
Journal:  Int J Radiat Oncol Biol Phys       Date:  2001-04-01       Impact factor: 7.038

8.  Prospective feasibility trial of radiotherapy target definition for head and neck cancer using 3-dimensional PET and CT imaging.

Authors:  Christopher Scarfone; William C Lavely; Anthony J Cmelak; Dominique Delbeke; William H Martin; Dean Billheimer; Dennis E Hallahan
Journal:  J Nucl Med       Date:  2004-04       Impact factor: 10.057

9.  The contribution of 18F-fluoro-2-deoxy-glucose positron emission tomographic imaging to radiotherapy planning in lung cancer.

Authors:  J D Kiffer; S U Berlangieri; A M Scott; G Quong; M Feigen; W Schumer; C P Clarke; S R Knight; F J Daniel
Journal:  Lung Cancer       Date:  1998-03       Impact factor: 5.705

10.  High accumulation of fluorine-18-fluorodeoxyglucose in turpentine-induced inflammatory tissue.

Authors:  S Yamada; K Kubota; R Kubota; T Ido; N Tamahashi
Journal:  J Nucl Med       Date:  1995-07       Impact factor: 10.057

View more
  18 in total

Review 1.  Positron Emission Tomography (PET) in Oncology.

Authors:  Andrea Gallamini; Colette Zwarthoed; Anna Borra
Journal:  Cancers (Basel)       Date:  2014-09-29       Impact factor: 6.639

2.  Respiratory gated [18F]FDG PET/CT for target volume delineation in stereotactic radiation treatment of liver metastases.

Authors:  R A Bundschuh; N Andratschke; J Dinges; M N Duma; S T Astner; M Brügel; S I Ziegler; M Molls; M Schwaiger; M Essler
Journal:  Strahlenther Onkol       Date:  2012-03-24       Impact factor: 3.621

3.  Variability of ¹⁸F-FDG-positive lung lesion volume by thresholding.

Authors:  Eric Laffon; Henri de Clermont; Roger Marthan
Journal:  Eur Radiol       Date:  2012-10-20       Impact factor: 5.315

Review 4.  The use of FDG-PET to target tumors by radiotherapy.

Authors:  Guido Lammering; Dirk De Ruysscher; Angela van Baardwijk; Brigitta G Baumert; Jacques Borger; Ludy Lutgens; Piet van den Ende; Michel Ollers; Philippe Lambin
Journal:  Strahlenther Onkol       Date:  2010-08-30       Impact factor: 3.621

5.  68Ga-PSMA-PET/CT imaging of localized primary prostate cancer patients for intensity modulated radiation therapy treatment planning with integrated boost.

Authors:  Lena Thomas; Steffi Kantz; Arthur Hung; Debra Monaco; Florian C Gaertner; Markus Essler; Holger Strunk; Wolfram Laub; Ralph A Bundschuh
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-02-21       Impact factor: 9.236

Review 6.  Prognostic value of metabolic tumor burden in lung cancer.

Authors:  Piotr Obara; Yonglin Pu
Journal:  Chin J Cancer Res       Date:  2013-12       Impact factor: 5.087

7.  Impact of rigid and nonrigid registration on the determination of 18F-FDG PET-based tumour volume and standardized uptake value in patients with lung cancer.

Authors:  Aleksandar Grgic; Elena Ballek; Jochen Fleckenstein; Norbert Moca; Stephanie Kremp; Andrea Schaefer; Jan-Martin Kuhnigk; Christian Rübe; Carl-Martin Kirsch; Dirk Hellwig
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-01-22       Impact factor: 9.236

8.  A contrast-oriented algorithm for FDG-PET-based delineation of tumour volumes for the radiotherapy of lung cancer: derivation from phantom measurements and validation in patient data.

Authors:  Andrea Schaefer; Stephanie Kremp; Dirk Hellwig; Christian Rübe; Carl-Martin Kirsch; Ursula Nestle
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-07-26       Impact factor: 9.236

9.  Application of machine learning methodology for PET-based definition of lung cancer.

Authors:  A Kerhet; C Small; H Quon; T Riauka; L Schrader; R Greiner; D Yee; A McEwan; W Roa
Journal:  Curr Oncol       Date:  2010-02       Impact factor: 3.677

10.  Quality assurance of positron emission tomography/computed tomography for radiation therapy.

Authors:  Lei Xing
Journal:  Int J Radiat Oncol Biol Phys       Date:  2008       Impact factor: 7.038

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.